Extensive Stage Small Cell Lung Cancer Market - A Global and Regional Analysis: Focus on Epidemiology, Product, and Region - Analysis and Forecast, 2022-2032

Dec 2022| BIS707A| BIS Research

Report Highlights

Regionally, according to BIS Research estimates about the target patient pool of extensive stage small cell lung cancer, the U.S. and the U.K. occupy the top position among the seven major markets, followed by Germany and Japan, with disease showing a relatively slow but increasing trend.

Global Extensive Stage Small Cell Lung Cancer Market Overview

Extensive stage small cell lung cancer is extremely aggressive sub-type of small cell lung cancer. Small cell lung itself is a sub-type of lung cancer which accounts for less than 20% cases. The treatment of extensive stage small cell lung cancer has been extremely challenging owing to poor survival rate of the patients. The median overall survival reported among the extensive stage small cell lung cancer patients has been slightly above a year while the overall progression free survival is reported to be of six months. Before the emergence of immune checkpoint inhibitors, traditional chemotherapy which included etoposide in combination with platinum (cisplatin or carboplatin) were the treatment mainstay however since the approval of immune checkpoint inhibitors; these have been included in the standard treatment regimen along with chemotherapy.

The Growing Prevalence of Extensive Stage Small Cell Lung Cnacer

The prevalence of extensive stage small lung cancer is estimated to increase in five of the seven major markets included in the study. Geographically, the U.S. remains at the top with an estimated prevalence for 2021 of more than 47,000 patients followed by the U.K. with over 8,500 patients. The prevalence is forecasted to be growing at a CAGR of 2.61% and 1.61% respectively for the U.S. and the U.K for the period 2022-2032.

Competitive Landscape

The current global extensive stage small cell lung cancer market has two approved immune checkpoint inhibitors namely Imfinzi (Durvalumab) from AstraZeneca PLC and Tecentriq (Atezolizumab) from F. Hoffmann La-Roche Ltd. Zepzelca (Lurbinectedine) from Jazz Pharmaceuticals Plc and Cosela (Trilaciclib) from G1 Therapeutics Inc. are other two products approved for the treatment of extensive stage small cell lung cancer patients.

Since, the introduction of immune checkpoint inhibitors to the extensive stage small cell lung cancer treatment, the competition in the global extensive stage small cell lung cancer market has significantly increased. F. Hoffmann La-Roche Ltd. and AstraZeneca Plc are the leading players among the companies having immune checkpoint inhibitor portfolio in the global extensive stage small cell lung cancer market. The companies having immune checkpoint inhibitors under clinical development have also added extensive stage small cell lung cancer treatment to their portfolio.

Currently there are four products available in the market which are patented. The chemotherapeutic products which constituted the standard of care have all become generic. There is a rich clinical pipeline of extensive stage small cell lung cancer maket with dominance of immune checkpoint inhibitors along with bispecific antibodies.

Segmentation:

Within the research report, the segmentation has made on the basis of:

  • Existing as well as Expected competition in the global extensive stage small cell lung cancer market. Commercial and Clinical products constitute “Products” segment., and
  • Region is the other segment which covers the seven major markets (the U.S., the U.K., Germany, France, Italy, Spain, and Japan).

Demand – Drivers and Challenges

Some of the potential drivers identified by BIS Research includes:

  • Potential therapeutic effects of immune checkpoint inhibitors in improving overall survival among cancer patients
  • Treatment directed toward decreasing the chemotherapy induced toxic effects

There are some challenges identified for the global extensive stage small cell lung cancer market include; treatment related toxic effects, lack of effective diagnostic tools/methods among others.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2022-2032
Segments covered Products, Region
Industry covered BIS Healthcare
Countries covered U.S., U.K., Germany, France, Italy, Spain, Japan
Companies studied
F. Hoffmann-La Roche Ltd
AstraZeneca PLC
Jazz Pharmaceuticals Plc
G1 Therapeutics Inc.
Shanghai Henlius Biotech, Inc.
Lee's Pharmaceutical Limited
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Beigene Ltd.

Frequently Asked Questions (FAQs)

How can this report add value to an organization?

Product/Innovation Strategy: The report provides an insight into estimated patient population eligible to receive treatment in the seven major market, with a view where the disease is on a decline and where it is showing an increasing trend. Additionally, the report provides an exhaustive list of pipeline products along with their developmental details which are currently in the development for extensive stage small cell lung cancer treatment. This can help organizations in assess the research activities, potential candidates to enter first into the market as well it can help the organization to assess where should they place themselves in order to get maximum benefit.

Growth/Marketing Strategy: The several growth strategies identified in the report include increased focus toward development of immunotherapies, use of immunotherapies in combination with existing standard treatment options, expanding the market reach by entering into licensing agreement with potential players.

Competitive Strategy: Key players in the global extensive stage small cell lung cancer market were analyzed and profiled in the study, who have commercially available treatment for extensive stage small cell lung cancer. Moreover, a detailed competitive benchmarking of the players operating in the global extensive stage small cell lung cancer market has been included to help the reader understand how players stand against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Companies Profiled

  • F. Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • Jazz Pharmaceuticals Plc
  • G1 Therapeutics Inc.
  • Shanghai Henlius Biotech, Inc.
  • Lee's Pharmaceutical Limited
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Beigene Ltd.

BIS Research is a global B2B market intelligence and advisory firm focusing on those emerging technological trends which are likely to disrupt the dynamics of the market.

With over 150 market research reports published annually, BIS Research focuses on high technology verticals such as 3D Printing, Advanced Materials and Chemicals, Aerospace and Defense, Automotive, Healthcare, Electronics and Semiconductors, Robotics and UAV, and other emerging technologies.

Our in-depth market intelligence reports focus on the market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

BIS Research
Price: $5250

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS